Silence Therapeutics Announces Results of 2026 Annual General Meeting
On June 16, 2026, Silence Therapeutics plc held its 2026 Annual General Meeting of Shareholders (AGM). During the meeting, shareholders voted on and approved nine resolutions. Key outcomes included the re-appointment of Rhonda Hellums and James Ede-Golightly as directors of the Company. Additionally, shareholders approved, on an advisory basis, the compensation of the Companyβs named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Other approved measures included the adoption of the 2025 U.K. statutory annual accounts, approval of the directors' remuneration report, and the authorization of the Audit & Risk Committee to set auditor remuneration. All resolutions passed with significant majorities. The filing was signed by Iain Ross, who serves as the Interim Principal Executive Officer and Chairman of the Board.